SuperworthCore Scientific CORZ
- Market cap
- $4.2B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −22.8%
Core Scientific's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $112.9M−31% | $141.9M+17% | $179.3M+49% | $141.1M+11% | $95.4M−16% | $94.9M−33% | $79.5M−56% | $78.6M−44% | $81.1M−15% | n/a | $115.2M+45% | $164.2M+109% | |
| Cost of revenue | $97.5M−49% | $102.6M−39% | $101.6M+14% | $102.3M+14% | $95.5M−2% | $90.2M−12% | $71.3M−30% | $73.6M−28% | $77.2M−19% | n/a | $85.1M+19% | $94.2M+28% |
| Gross profit | $15.4M | $39.3M | $77.6M+144% | $38.8M+5% | −$156K | $4.8M−88% | $8.2M−89% | $5M−87% | $3.9M | n/a | $30.1M+267% | $70M+1294% |
| R&D | $2.3M−64% | $1.9M−29% | $1.8M+27% | $2.2M+33% | $2.8M+26% | $5M+167% | n/a | n/a | n/a | n/a | n/a | n/a |
| SG&A | $24.6M−43% | $28.1M−30% | $16.9M−26% | $31.4M+23% | $40.3M+64% | $31.8M+13% | $32.3M+91% | $45.3M+44% | $69.4M+72% | n/a | $44.8M+39% | $49.4M+9% |
| −$12M−97% | $3.9M | $55.2M+627% | −$90.7M | −$41.2M+242% | −$39.8M | −$47M | −$26.3M−71% | −$54.8M+33% | n/a | −$310.4M+560% | −$78.5M+199% | |
| Interest expense | $2.2M−92% | $83.9M+280% | $14.1M+8873% | $14.8M | $7.1M+222% | $1.1M−99% | $4.7M−66% | $4.8M−68% | n/a | n/a | $8.2M+72% | $40.6M+755% |
| Pre-tax income | −$41M−90% | −$195.4M−57% | $210.9M | −$902M+9779% | −$455.1M+1009% | −$265.2M+36% | $576.5M+173% | −$936.6M+4% | −$143.9M−68% | n/a | −$346.6M | −$1.2B+23% |
| $114K−99% | $336K | $206K+98% | $144K+12% | $134K+18% | $375K+12% | $205K−1% | $158K+10% | $125K−7% | n/a | $600K+193% | $1.9M+1107% | |
| Net income | −$41.1M−91% | −$195.7M−55% | $210.7M | −$902.2M+9643% | −$455.3M+1006% | −$291.1M+49% | $576.3M+174% | −$936.8M+4% | −$144M−68% | $216M | −$347.2M | −$1.2B+23% |
| −$0.11−91% | −$0.51−52% | $0.78 | −$5.05+25150% | −$1.17+964% | −$0.80+57% | $1.24+59% | −$0.04−99% | −$0.45−62% | $0.60 | −$1.06 | −$3.32+8200% | |
| 382.5M+8% | 385.1M−6% | 282.5M−25% | 178.5M−53% | 292.5M−24% | 264.1M−31% | 363.3M+29% | 318M+78% | 318.6M+9% | 320.2M+21% | 322.9M−11% | 325.3M+2% |
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY21 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Financial - Credit Services nearest Core Scientific's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CORZCore Scientific | $4.2B | n/m | n/a | n/m | n/m | n/m | |
| PAYPaymentus | $4.2B | 50.5× | 97.8× | 3.1× | +30% | 6.2% | |
| NNINelnet | $4.4B | 14.7× | 11.2× | 3.7× | +6% | 25.8% | |
| ENVAEnova International | $4B | 11.4× | 11.4× | 1.1× | +20% | 10.5% | |
| SEZLSezzle | $4.4B | 29.0× | 27.8× | 8.4× | +43% | 30.4% | |
| DAVEDave | $4.5B | 23.0× | 22.7× | 7.0× | +49% | 34.6% | |
| BFHBread Financial | $3.8B | 7.8× | 8.1× | 1.0× | +4% | 14.4% | |
| SLMSLM | $3.5B | 7.0× | 8.6× | 2.0× | −7% | 31.7% | |
| TNETTrinet | $3.5B | 20.3× | 19.2× | 0.7× | −3% | 3.6% | |
| FIGRFigure Technology Solutions | $5.2B | 24.2× | 33.2× | 7.3× | +89% | 33.5% | |
| RELYRemitly Global | $5.3B | 17.9× | 55.1× | 2.9× | +24% | 16.9% | |
| Peer median | $4.3B | 19.1× | 20.9× | 3.0× | +22% | 21.3% |
Investors who own it
Investors we follow who held Core Scientific at the end of Jun 30, 2026, from their 13F filings.
- Chase ColemanTiger Global Management0.1% of portfolionew
- Dan LoebThird Point0.0% of portfolionew
More on Core Scientific
Each number over time
Its groups
About
- Industry
- Financial - Credit Services
- Sector
- Financial Services
Valuation data, not investment advice. Prices as of .